EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 35 / Numéro 5 (Mai 2019) Med Sci (Paris), 35 5 (2019) 431-439 Références
Open Access
Numéro
Med Sci (Paris)
Volume 35, Numéro 5, Mai 2019
Page(s) 431 - 439
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2019076
Publié en ligne 22 mai 2019
  1. World health organization Global hepatitis report, 2017. 2017 ; Geneva: WHO, [Google Scholar]
  2. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012 ; 57 : 167–185. [CrossRef] [PubMed] [Google Scholar]
  3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015 ; 136 : E359–E386. [CrossRef] [PubMed] [Google Scholar]
  4. Graber-Stiehl I.. The silent epidemic killing more people than HIV, malaria or TB. Nature. 2018 ; 564 : 24. [CrossRef] [PubMed] [Google Scholar]
  5. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut. 1996 ; 38 : S5–12. [CrossRef] [PubMed] [Google Scholar]
  6. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015 ; 386 : 1546–1555. [CrossRef] [PubMed] [Google Scholar]
  7. Bah E, Carrieri MP, Hainaut P, et al. 20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia. West Africa. PLoS One. 2013 ; 8 : e75775. [CrossRef] [PubMed] [Google Scholar]
  8. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 ; 65 : 87–108. [CrossRef] [PubMed] [Google Scholar]
  9. International Agency for Research on Cancer Some traditional herbal medicines, some mycotoxins, naphthalene and styrene: this publication represents the views and expert opinions of an IARC working group on the evaluation of carcinogenic risks to hHumans, which met in Lyon, 12–19 February 2002. 2002 ; Lyon: IARC: 590. [Google Scholar]
  10. Kirk GD, Lesi OA, Mendy M, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005 ; 24 : 5858–5867. [Google Scholar]
  11. Kuniholm MH, Lesi OA, Mendy M, et al. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia. West Africa. Environ Health Perspect. 2008 ; 116 : 1553–1557. [CrossRef] [PubMed] [Google Scholar]
  12. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 ; 351 : 1521–1531. [Google Scholar]
  13. Robotin MC, Kansil MQ, George J, et al. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res. 2010 ; 10 : 215. [CrossRef] [PubMed] [Google Scholar]
  14. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma: an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006 ; 23 : 1535–1547. [Google Scholar]
  15. EASL, EORTC. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 : 908–43. [CrossRef] [PubMed] [Google Scholar]
  16. Yang JD, Mohamed EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017 ; 2 : 103–111. [CrossRef] [PubMed] [Google Scholar]
  17. Shimakawa Y, Takao Y, Anderson ST, et al. The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia. West Africa. Palliat Med. 2015 ; 29 : 184–185. [Google Scholar]
  18. Shimakawa Y, Lemoine M. Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2017 ; 2 : 393. [CrossRef] [PubMed] [Google Scholar]
  19. Njai HF, Shimakawa Y, Sanneh B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia. Western Africa. J Clin Microbiol. 2015 ; 53 : 1156–1163. [PubMed] [Google Scholar]
  20. Ladep NG, Dona AC, Lewis MR, et al. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology. 2014 ; 60 : 1291–1301. [CrossRef] [PubMed] [Google Scholar]
  21. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther. 2016 ; 44 : 1005–1017. [Google Scholar]
  22. Lemoine M, Shimakawa Y, Njie R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the prevention of liver fibrosis and cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016 ; 4 : e559–e567. [Google Scholar]
  23. Shimakawa Y, Pourette D, Bainilago L, et al. Improving communication about viral hepatitis in Africa. Lancet Infect Dis. 2017 ; 17 : 688–689. [CrossRef] [PubMed] [Google Scholar]
  24. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 ; 50 : 1–662. [PubMed] [Google Scholar]
  25. Marcellin P, Zoulim F, Hézode C, et al. Effectiveness and safety of Tenofovir Disoproxil Fumarate in chronic hepatitis B: A 3-year, prospective, real-world study in France. Dig Dis Sci. 2016 ; 61 : 3072–3083. [CrossRef] [PubMed] [Google Scholar]
  26. Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016 ; 16 : 1399–1408. [CrossRef] [PubMed] [Google Scholar]
  27. Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis. Lancet Glo Health. 2016 ; 4 : e568–e578. [CrossRef] [Google Scholar]
  28. Ghosh S, Sow A, Guillot C, et al. Implementation of an in-house quantitative real-time polymerase chain reaction method for hepatitis B virus quantification in West African countries. J Viral Hepat. 2016 ; 23 : 897–904. [CrossRef] [PubMed] [Google Scholar]
  29. Ni Y, Sonnabend J, Seitz S, et al. The pre-S2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. J Virol. 2010 ; 84 : 3879–3888. [PubMed] [Google Scholar]
  30. Hsieh YH, Chang YY, Su IJ, et al. Hepatitis B virus pre-S 2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis: HBV pre-S2 mutant LHBS, Nijmegen breakage and importin α1. J Pathol. 2015 ; 236 : 337–347. [PubMed] [Google Scholar]
  31. Shariff MIF, Ladep NG, Cox IJ, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J. Proteome Res.. 2010 ; 9 : 1096–1103. [Google Scholar]
  32. Shimakawa Y, Njie R, Ndow G, et al. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. Journal of Hepatology. 2018 ; 69 : 776–784. [CrossRef] [PubMed] [Google Scholar]
  33. Lemoine M, Shimakawa Y, Njie R, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in the Gambia. Aliment Pharmacol Ther. 2014 ; 39 : 188–196. [Google Scholar]
  34. Lemoine M, Shimakawa Y, Goldin R, et al. P1019 validation and comparison of non-invasive markers of liver fibrosis in West-African patients with chronic hepatitis B living in the Gambia. J Hepatol. 2014 ; 60 : S414–S415. [Google Scholar]
  35. Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016 ; 65 : 1369–1376. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.